Prenatal testing of trisomy

Non-Invasive Prenatal Testing for Trisomy: Why It Carries Fewer Risks

Prenatal testing for trisomy is recommended for women with heightened genetic risks. The most commonly prescribed procedure is amniocentesis, an invasive procedure that tests fetal fluids using a special needle. But this procedure is not without risk: while the chances of losing the fetus are small, it remains a concern. In response, Eurofins Biomnis has developed non-invasive genetic screening tests that deliver fast, accurate results. Their NIPT (non-invasive prenatal testing) kit draws analysis from a maternal blood sample. With a Prenatal testing for trisomy we can determine whether the risk of fetal defects is high or low, reducing invasive procedures by up to 95%.

Prenatal testing for trisomy 21 (Down Syndrome) is one of the most common procedures prescribed to at-risk expectant mothers. The non-invasive tests offered by Eurofins Biomnis efficiently detect factors of abnormal pregnancy by drawing a small maternal blood sample. Aside from maternal DNA, the blood of pregnant women contains fetal DNA originating from the placenta. The identification of fetal DNA in the maternal blood sample, in tandem with a new technology called Next Generation Sequencing that is capable of counting all genetic material sequences in the sample, permits the rapid and accurate detection of abnormalities. Prenatal testing for trisomy 21 no longer needs to mean taking unwelcome risks.

To rule out common pregnancy risks, scheduling an NIPT procedure with a primary care physician or other healthcare provider offers patients a safe alternative to invasive tests, including for Edwards' Syndrome (trisomy 18). The risk-free prenatal testing for trisomy 18 offered by Eurofins Biomnis can be ordered to your physician's practice and carried out there, or at a partner laboratory. During your consultation, your healthcare provider will prescribe an NIPT and ask you to sign an informed consent form, which is mandatory for all genetic tests. This form of prenatal testing for trisomy 18 is quick, and results for the Edwards' Syndrome blood test are generally available after around seven days.

Can Patau Syndrome be detected prenatally without relying on invasive testing methods? The answer is yes. Non-invasive prenatal testing for trisomy 13 is remarkably accurate, offering a detection rate of over 99%. This allows healthcare providers to frequently eliminate all need to undergo invasive forms of diagnosis. How does this work? Besides maternal DNA, the blood of pregnant women contains fetal DNA. The NIPT test developed by Eurofins Biomnis uses an innovative technology to help determine whether a trisomy is present. Thanks to these ground-breaking developments, prenatal testing for Patau Syndrome can be carried out with minimal risk.